This site is intended for healthcare professionals

Amgen submits sotorasib NDA to the FDA for advanced or metastatic non-small cell lung cancer with KRAS G12C mutation.

Read time: 1 mins
Last updated:28th Jun 2021
Published:18th Dec 2020
Condition: NSCLC/KRAS G12C
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest